Key result
Ginsenoside Rg2 pretreatment attenuates Trastuzumab-induced LV dysfunction and cardiomyocyte apoptosis in preclinical models.
Why the study?
Trastuzumab has significant cardiotoxicity, and this study investigated whether ginsenoside Rg2 attenuates trastuzumab-induced cardiotoxicity.
Does Ginsenoside Rg2 prevent Trastuzumab-induced cardiotoxicity in preclinical models?
Population
Wistar rats and primary human cardiomyocytes
Comparison
Trastuzumab with Rg2 pretreatment vs trastuzumab alone
Design
Preclinical animal and in vitro study
Authors
Loading...
Hypothesis-generating for Ginsenoside Rg2 in trastuzumab cardiotoxicity; prospective human trials needed before any clinical consideration.
Does Ginsenoside Rg2 prevent Trastuzumab-induced cardiotoxicity in preclinical models?
Ginsenoside Rg2 attenuates trastuzumab-induced cardiotoxicity by downregulating proapoptotic proteins, suggesting a potential therapeutic role in preventing cardio-oncologic complications.
Liu et al. (2022) studied Trastuzumab-induced cardiotoxicity. Ginsenoside Rg2 vs. Trastuzumab alone was evaluated on LV dysfunction and apoptosis. Pretreatment with Ginsenoside Rg2 attenuated Trastuzumab-induced left ventricular dysfunction in rats and reduced apoptosis in human cardiomyocytes.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: